Argenx to Buy Unnatural Products for Up to $1.15 Billion
By Adria Calatayud
Argenx said it agreed to acquire California-based biotech company Unnatural Products for up to $1.15 billion, bringing peptide-discovery technology in-house.
The Amsterdam-based biotech company said Monday that it will pay $550 million in cash upfront for Unnatural Products, and up to $595 million tied to the achievement of certain development and regulatory milestones. Argenx already owned a minority stake in Unnatural Products and will acquire all remaining shares, it said.
The deal aims to combine Argenx's antibody-engineering capabilities with Unnatural Products' expertise in peptides, expanding its ability to develop oral or long-acting treatments for immune-mediated diseases, Argenx said.
The boards of both companies have approved the deal, which is expected to close by the end of the year, Argenx said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
November 09, 2026 01:42 ET (06:42 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
These Overvalued Stocks Have Plenty of Room to Fall
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
The 10 Best Companies to Invest in Now
4 Big Impacts From the US Midterm Elections for Investors
United States